Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:CSII
Previous Symbol
CUSIP14161910
Phone651-259-1600
Debt
Debt-to-Equity Ratio0.16
Current Ratio4.54
Quick Ratio4.04
Price-To-Earnings
Trailing P/E Ratio575.80
Forward P/E Ratio-319.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.04 million
Price / Sales4.60
Cash Flow$0.1602 per share
Price / Cash179.73
Book Value$4.04 per share
Price / Book7.13
Profitability
EPS (Most Recent Fiscal Year)$0.05
Net Income$1.71 million
Net Margins0.36%
Return on Equity0.62%
Return on Assets0.41%
Miscellaneous
Employees652
Outstanding Shares34,700,000
Market Cap$1.06 billion
OptionableOptionable
Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions
What is Cardiovascular Systems' stock symbol?
Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."
How were Cardiovascular Systems' earnings last quarter?
Cardiovascular Systems Inc (NASDAQ:CSII) posted its quarterly earnings results on Tuesday, October, 30th. The medical device company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.03. The medical device company earned $56.27 million during the quarter, compared to the consensus estimate of $55.96 million. Cardiovascular Systems had a return on equity of 0.62% and a net margin of 0.36%. View Cardiovascular Systems' Earnings History.
When is Cardiovascular Systems' next earnings date?
What guidance has Cardiovascular Systems issued on next quarter's earnings?
Cardiovascular Systems updated its FY 2019 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $240-250 million, compared to the consensus revenue estimate of $244.36 million.
What price target have analysts set for CSII?
7 Wall Street analysts have issued 12-month price targets for Cardiovascular Systems' stock. Their predictions range from $23.00 to $50.00. On average, they expect Cardiovascular Systems' stock price to reach $37.00 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View Analyst Price Targets for Cardiovascular Systems.
What is the consensus analysts' recommendation for Cardiovascular Systems?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiovascular Systems.
What are Wall Street analysts saying about Cardiovascular Systems stock?
Here are some recent quotes from research analysts about Cardiovascular Systems stock:
- 1. According to Zacks Investment Research, "Cardiovascular Systems exited first-quarter fiscal 2019 on a mixed note. The company continued to see increased revenues from Atherectomy franchises, growing international sales of OAS and top-line contributions from its emerging product pipeline. We are also upbeat about Cardiovascular Systems’ recent announcement of the first global commercial use of Stealth 360 Peripheral OAS in Hong Kong. Further, the company is progressing well with the international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside the United States and Japan. According to management, the company saw the strongest quarterly growth in the first quarter in the last 18 months. Over the past six months, Cardiovascular Systems has outperformed its industry. On the flip side, the company faces cut-throat competition in the niche space. Further, its failure to enter global markets might affect results." (11/12/2018)
- 2. Needham & Company LLC analysts commented, "CSII’s F1Q19 revenue beat while EPS missed consensus and management maintained FY19 revenue guidance. While CSII should continue to benefit from the Japanese launch, an exclusive international distribution agreement (OrbusNeich), new support products, and building rep productivity, we believe there is execution risk in CSII’s long-term transformation (see our analyst meeting note here). Given these points, increasingly difficult comps in FY19, and our belief that CSII shares are fairly valued, we maintain our Hold rating." (10/31/2018)
Has Cardiovascular Systems been receiving favorable news coverage?
Media stories about CSII stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardiovascular Systems earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the medical device company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Cardiovascular Systems' key competitors?
Some companies that are related to Cardiovascular Systems include Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), AtriCure (ATRC), Nevro (NVRO), Luminex (LMNX), K2M Group (KTWO), Orthofix Medical (OFIX) and Cryolife (CRY).
Who are Cardiovascular Systems' key executives?
Cardiovascular Systems' management team includes the folowing people:
- Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 58)
- Mr. Jeffrey S. Points, Chief Financial Officer (Age 41)
- Ms. Rhonda J. Robb, Chief Operating Officer (Age 50)
- Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 46)
- Ms. Laura J. Gillund, Chief Talent Officer (Age 57)
Who are Cardiovascular Systems' major shareholders?
Cardiovascular Systems' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.43%), Partner Fund Management L.P. (2.93%), Renaissance Technologies LLC (2.55%), Frontier Capital Management Co. LLC (2.15%), First Light Asset Management LLC (1.40%) and FMR LLC (1.25%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Martha Goldberg Aronson, Sandra Sedo and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.
Which major investors are selling Cardiovascular Systems stock?
CSII stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., FMR LLC, Frontier Capital Management Co. LLC, Gabelli Funds LLC, Thrivent Financial for Lutherans, Credit Suisse AG, Sterling Capital Management LLC and BlueMountain Capital Management LLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, Jeffrey S Points and Sandra Sedo. View Insider Buying and Selling for Cardiovascular Systems.
Which major investors are buying Cardiovascular Systems stock?
CSII stock was purchased by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Fuller & Thaler Asset Management Inc., Castleark Management LLC, TIAA CREF Investment Management LLC, Renaissance Technologies LLC, BlackRock Inc., American Century Companies Inc. and Man Group plc. Company insiders that have bought Cardiovascular Systems stock in the last two years include Martha Goldberg Aronson and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.
How do I buy shares of Cardiovascular Systems?
Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiovascular Systems' stock price today?
One share of CSII stock can currently be purchased for approximately $28.79.
How big of a company is Cardiovascular Systems?
Cardiovascular Systems has a market capitalization of $1.06 billion and generates $217.04 million in revenue each year. The medical device company earns $1.71 million in net income (profit) each year or $0.05 on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe.
What is Cardiovascular Systems' official website?
How can I contact Cardiovascular Systems?
Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]
MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
